HIV Antibody Escape Mapped in Prevention Trial

HIV antibody escape has now been mapped in real infections. A study published in Nature Microbiology on October 15 found that the virus developed new mutations to dodge the preventive antibody VRC01 after breakthrough infections in the Antibody-Mediated Prevention (AMP) trials. Researchers analyzed 11,730 HIV envelope sequences from 47 trial participants whose infections began with viruses susceptible to the antibody. New escape mutations emerged in eight of the 26 recipients who had received VRC01, a rate of about 31 percent, while none appeared in the 21 participants who received a placebo.

The AMP trials were the first large test of whether lab-made broadly neutralizing antibodies could prevent HIV infection in people. More than 4,600 volunteers enrolled across Africa, the Americas and Europe to receive VRC01, an antibody that targets many strains of the virus. Unlike a vaccine, the treatment does not wait for the body to build its own defenses; it delivers protection directly through infusions. In the end, VRC01 did not reduce overall infection rates by a meaningful amount, although it cut infections caused by highly sensitive strains by roughly three quarters.

How a single mutation broke through

One result startled the virologists. VRC01 attaches to the exact part of HIV that grabs the receptor on human immune cells, the step the virus must complete to enter the cell. Carolyn Williamson, a virologist at the University of Cape Town's Institute of Infectious Disease and Molecular Medicine and the National Health Laboratory Service, expected that target to be hard for the virus to change without breaking itself. Instead, a single genetic change was enough to make HIV resistant, and the escaped viruses arrived by several different genetic routes. Penny Moore of Wits University's Antibody Immunity Research Unit said the pattern shows how flexible the virus remains even when an antibody aims at one of its most critical weak points.

The dosage turned out to be part of the story. Larry Corey of the Fred Hutch Cancer Center, a lead investigator of the AMP trials, said the team had underestimated how much antibody the body needs to stay protected. Antibody levels fell between infusions, and during those low periods the less sensitive viruses had room to break through. The finding points to a practical lesson for the next generation of prevention: keeping antibody concentrations high through the full dosing cycle matters as much as choosing the right antibody.

Rare mutations may come at a cost

HIV antibody escape appears to come with an evolutionary price. Most of the escape mutations the team found show up in fewer than one in a hundred HIV sequences circulating around the world. That rarity suggests the changes may weaken the virus in some way, although the researchers stressed that the fitness cost is only a possibility for now. They still need to learn whether the resistant viruses stick around once antibody pressure disappears or revert to a more successful form. Moore said that if future antibody combinations each force the virus to pay such a price, it may eventually exhaust its options for escape.

The mutations were only visible because of deep sequencing, which exposed the full extent of HIV antibody escape in each patient. HIV exists inside each person as a shifting cloud of related viruses, and conventional sequencing reads the most common variants while missing rare ones. The team examined large numbers of viruses from each participant, and many of the escape variants made up only a tiny fraction of that population. Deep sequencing caught what standard methods would have overlooked, according to the researchers, with some escape mutations present at frequencies of two percent or lower. James Mullins of the University of Washington, a senior author of the paper, said the method drew on sequencing platforms built by the South African and American laboratories.

The results also point to a way forward against HIV antibody escape. VRC01 is now an older-generation antibody, and the researchers tested whether viruses that escaped it could also resist newer ones. Some of the mutations reduced sensitivity to other antibodies aimed at the same site, but the more potent antibodies N6 and 1-18 largely stayed effective. That outcome supports testing higher antibody concentrations and combinations that attack HIV in different ways, which would raise the barrier to resistance. The same lesson applies to vaccines: the goal is to prompt the immune system against several vulnerable parts of the virus at once rather than a single target. The samples collected for the AMP trials, the researchers noted, are still producing insights years after the trial ended.

The study, reported by Wits University and published in Nature Microbiology, was a collaboration between South African researchers and trial sites, Fred Hutch Cancer Center, the University of Washington and other American institutions.